HomeCompareEDR vs ABBV

EDR vs ABBV: Dividend Comparison 2026

EDR yields 0.82% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.3K in total portfolio value
10 years
EDR
EDR
● Live price
0.82%
Share price
$29.25
Annual div
$0.24
5Y div CAGR
-25.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$4.46
Full EDR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EDR vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEDRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EDR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EDR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EDR
Annual income on $10K today (after 15% tax)
$69.74/yr
After 10yr DRIP, annual income (after tax)
$3.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,052.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EDR + ABBV for your $10,000?

EDR: 50%ABBV: 50%
100% ABBV50/50100% EDR
Portfolio after 10yr
$61.2K
Annual income
$12,388.11/yr
Blended yield
20.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EDR
Analyst Ratings
9
Buy
6
Hold
1
Sell
Consensus: Buy
Price Target
$28.75
-1.7% upside vs current
Range: $25.00 — $36.00
Altman Z
0.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EDR buys
0
ABBV buys
0
No recent congressional trades found for EDR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEDRABBV
Forward yield0.82%3.06%
Annual dividend / share$0.24$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-25.4%40.6%
Portfolio after 10y$20.0K$102.3K
Annual income after 10y$4.46$24,771.77
Total dividends collected$230.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$28.75$256.15

Year-by-year: EDR vs ABBV ($10,000, DRIP)

YearEDR PortfolioEDR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,761$61.21$11,550$430.00$789.00ABBV
2$11,560$45.92$13,472$627.96$1.9KABBV
3$12,404$34.40$15,906$926.08$3.5KABBV
4$13,298$25.73$19,071$1,382.55$5.8KABBV
5$14,248$19.23$23,302$2,095.81$9.1KABBV
6$15,260$14.37$29,150$3,237.93$13.9KABBV
7$16,339$10.73$37,536$5,121.41$21.2KABBV
8$17,491$8.01$50,079$8,338.38$32.6KABBV
9$18,721$5.98$69,753$14,065.80$51.0KABBV
10$20,036$4.46$102,337$24,771.77$82.3KABBV

EDR vs ABBV: Complete Analysis 2026

EDRStock

Endeavor Group Holdings, Inc. operates as an entertainment, sports, and content company in the United States, the United Kingdom, and internationally. It operates in three segments: Owned Sports Properties, Events, Experiences & Rights, and Representation. The Owned Sports Properties segment operates a portfolio of sports properties, including Ultimate Fighting Championship, Professional Bull Rider, Euroleague, and Diamond Baseball Holdings, that license broadcast and other intellectual property rights and operate exclusive live events. The Events, Experiences & Rights segment provides services to a portfolio of live events, including sporting events, fashion, art fairs and music, culinary, and lifestyle festivals. This segment also owns and operates the IMG Academy, an academic and sports training institution; and produces and distributes sports video programming. The Representation segment offers services to a diverse group of talent across entertainment, sports, and fashion, such as actors, directors, writers, athletes, models, musicians, and other artists in various mediums comprising film, television, art, books, and live events. This segment provides brand strategy, marketing, advertising, public relations, analytics, digital, activation, and experiential services to corporate and other clients; intellectual property licensing services to a portfolio of entertainment, sports, and consumer product brands; and content development, production, financing, sales, and advisory services for television properties, documentaries, feature films, and podcasts. The company was founded in 1898 and is based in Beverly Hills, California.

Full EDR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EDR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EDR vs SCHDEDR vs JEPIEDR vs OEDR vs KOEDR vs MAINEDR vs JNJEDR vs MRKEDR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.